WY-14643 (Pirinixic Acid): Protocols and Innovations in Metabolic Research

Principle Overview: WY-14643 as a Selective PPARα Agonist

WY-14643, also known as Pirinixic Acid, stands at the forefront of metabolic disorder research as a highly potent and selective agonist of peroxisome proliferator-activated receptor alpha (PPARα). By binding to and activating PPARα, WY-14643 facilitates the regulation of lipid metabolism, inflammation, and energy homeostasis. Enhanced by aliphatic α-substitution, it also exerts balanced dual PPARα/γ agonist activity in the low micromolar range, opening avenues for insulin sensitivity enhancement and anti-inflammatory effects, particularly in endothelial cells.

As detailed in the product information, this compound is particularly noted for its ability to down-regulate VCAM-1 in endothelial cells, reduce inflammatory cell adhesion, and improve metabolic parameters in animal models without increasing body weight. These properties make WY-14643 (Pirinixic Acid) a benchmark tool for dissecting metabolic and inflammatory pathways.

Key Innovation from the Reference Study

The latest advances are exemplified by the YAP-TEAD mediates peroxisome proliferator-activated receptor α induced hepatomegaly and liver regeneration in mice study, which bridges the gap between PPARα activation and regenerative biology. This research established that PPARα activation by WY-14643 in mice not only accelerates hepatomegaly and liver regeneration but does so via a YAP-TEAD-dependent mechanism. This insight reframes the compound’s value beyond traditional metabolic endpoints, suggesting practical use in liver regeneration models and in studies of organ repair. Practically, this means that when selecting WY-14643 for metabolic or regenerative assays, researchers should consider both the phenotypic endpoints (such as liver mass or KI67 proliferation index) and the potential to modulate YAP-TEAD pathway activity for mechanistic dissection.

Experimental Workflow: Step-by-Step Protocol Enhancements

Deploying WY-14643 in the lab requires attention to its physicochemical properties and evidence-based dosing paradigms. The following protocol parameters reflect both product specifications and peer-reviewed studies:

Protocol Parameters

• Dissolution: Dissolve WY-14643 in DMSO at ≥16.2 mg/mL or in ethanol at ≥48.8 mg/mL (with ultrasonic assistance); warm at 37°C and use ultrasonic shaking for optimal solubility. The compound is insoluble in water.
• Animal model dosing: For studies of liver regeneration or metabolic regulation, administer WY-14643 intraperitoneally at 100 mg/kg/day for 5–10 days, as in the reference study.
• Oral administration (rodent metabolic studies): Dose at 3 mg/kg/day for 2 weeks; this regimen reduces plasma glucose, triglycerides, and leptin, and improves insulin sensitivity (see product details).

Workflow enhancements for cell-based assays include pre-treating endothelial cultures at 1–10 μM WY-14643 for 12–24 hours prior to inflammation induction, enabling robust assessment of anti-inflammatory endpoints such as VCAM-1 expression.

Advanced Applications and Comparative Advantages

WY-14643’s profile as a selective PPARα agonist with dual PPARα/γ activity unlocks a spectrum of advanced applications, from metabolic disorder research to regenerative medicine. In high fat-fed rat models, it demonstrates a unique capacity to reduce muscle and liver triglycerides and enhance insulin sensitivity without promoting weight gain. This positions it favorably against other PPAR agonists, which may carry adverse weight effects.

Crucially, the reference study’s demonstration that WY-14643 activates the YAP-TEAD axis during liver regeneration extends its application to tissue repair paradigms. Researchers can leverage this by combining WY-14643 treatment with genetic or pharmacological YAP-TEAD modulation to dissect the interplay between metabolism and regeneration.

For researchers focused on inflammation, the compound’s ability to down-regulate VCAM-1 in endothelial cells underpins its use as an anti-inflammatory agent in endothelial cells. This complements insights from the mechanistic rationale article, which details how dual PPARα/γ agonists like WY-14643 modulate inflammation and lipid metabolism with high fidelity.

Comparatively, while other selective PPARα agonists may lack dual receptor activity, WY-14643’s balanced action supports more comprehensive metabolic and immunological studies, as further explored in the translational research synthesis. That piece bridges multiomics evidence to next-generation workflow strategies—an extension of the reference study’s mechanistic focus into broader translational endpoints.

Troubleshooting and Optimization Tips

• Solubility issues: If precipitate forms during dissolution, ensure complete mixing by warming the solution to 37°C and applying ultrasonic agitation. Avoid water-based solvents due to poor solubility.
• Solution stability: Prepare fresh working solutions as stock solutions are not recommended for long-term storage. Store aliquots at -20°C and minimize freeze-thaw cycles to preserve activity.
• Batch variability: Always verify compound identity and purity using HPLC or MS if reproducibility issues arise, especially when switching vendors. APExBIO’s rigorous quality controls minimize such risks.
• Dose translation: When transitioning from in vitro to in vivo models, adjust doses according to published pharmacokinetics and metabolic rates; start with 1–10 μM for cell culture and 3–100 mg/kg for rodent models as benchmarks, then titrate to study-specific endpoints.
• Endpoint validation: Use qPCR for PPARα and downstream targets (e.g., VCAM-1, lipid metabolism genes), and complement with liver histology and serum biochemistry to confirm biological effect.

Outlook: Implications for Future Metabolic and Regenerative Studies

The reference study’s demonstration of YAP-TEAD pathway involvement in PPARα-mediated hepatomegaly and regeneration sets the stage for cross-disciplinary research into organ repair and metabolic health. As metabolic disorder models increasingly incorporate endpoints like tissue regeneration and inflammation resolution, WY-14643 (Pirinixic Acid) will remain a pivotal tool—especially in protocols that require tight control over insulin sensitivity and anti-inflammatory responses.

Building on the mechanistic and translational frameworks established in previous resources, future efforts are likely to focus on integrating WY-14643 into multi-omics workflows and combinatorial intervention studies. As always, APExBIO continues to support advanced research in this domain by ensuring the consistency, purity, and traceability of WY-14643 for both established and emerging applications.

Conclusion

WY-14643 (Pirinixic Acid) is not only a proven selective PPARα agonist but also a uniquely versatile tool for studies of lipid metabolism regulation, insulin sensitivity enhancement, and regenerative biology. The latest mechanistic insights into YAP-TEAD signaling amplify its value, making it indispensable for metabolic disorder research and beyond. For reliable supply and technical support, APExBIO’s WY-14643 (Pirinixic Acid) remains the trusted choice among researchers worldwide.